GENE vs. CLRB, IPA, IMNN, BCDA, BCTX, OMGA, ACXP, MYNZ, SNSE, and TXMD
Should you be buying Genetic Technologies stock or one of its competitors? The main competitors of Genetic Technologies include Cellectar Biosciences (CLRB), ImmunoPrecise Antibodies (IPA), Imunon (IMNN), BioCardia (BCDA), BriaCell Therapeutics (BCTX), Omega Therapeutics (OMGA), Acurx Pharmaceuticals (ACXP), Mainz Biomed (MYNZ), Sensei Biotherapeutics (SNSE), and TherapeuticsMD (TXMD). These companies are all part of the "pharmaceutical products" industry.
Genetic Technologies vs.
Genetic Technologies (NASDAQ:GENE) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, community ranking, risk, earnings and dividends.
Genetic Technologies has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.
Cellectar Biosciences received 82 more outperform votes than Genetic Technologies when rated by MarketBeat users. However, 55.33% of users gave Genetic Technologies an outperform vote while only 54.85% of users gave Cellectar Biosciences an outperform vote.
0.6% of Genetic Technologies shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 6.5% of Genetic Technologies shares are owned by insiders. Comparatively, 3.7% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Cellectar Biosciences has a consensus price target of $17.67, suggesting a potential upside of 5,526.33%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cellectar Biosciences is more favorable than Genetic Technologies.
Genetic Technologies has higher revenue and earnings than Cellectar Biosciences.
In the previous week, Genetic Technologies had 2 more articles in the media than Cellectar Biosciences. MarketBeat recorded 3 mentions for Genetic Technologies and 1 mentions for Cellectar Biosciences. Cellectar Biosciences' average media sentiment score of 0.00 beat Genetic Technologies' score of -0.05 indicating that Cellectar Biosciences is being referred to more favorably in the news media.
Summary
Genetic Technologies beats Cellectar Biosciences on 7 of the 13 factors compared between the two stocks.
Get Genetic Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for GENE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genetic Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:GENE) was last updated on 2/22/2025 by MarketBeat.com Staff
